

IDS 09/14/2006

2006

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number 09/965,738

Filing Date Sept. 27, 2001

First Named Inventor O'Brien, Timothy J.

Art Unit 1642

Examiner Name Nickol, Gary B.

Attorney Docket Number 110.018US1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
PR		Accession Number AA640072, GenBank nucleotide sequence database, Oct. 27, 1997.	

Examiner
Signature

/Peter Reddig/

Date
Considered


05/13/2006


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

 <p>INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)</p>				Docket Number (Optional) 022438.43865		Application Number 09/965,738		
				Applicant(s) Timothy J. O'Brien				
				Filing Date 9/27/01		Group Art Unit 1642		
U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
PR	AA	6,335,194	1-1-2002	Bennett et al.	435/375		2-2-2000	
PR	BB	6,451,602	9-17-2002	Popoff et al.	435/375		3-2-2000	
U.S. PATENT APPLICATION PUBLICATIONS								
*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS								
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
EXAMINER /Peter Reddig/				DATE CONSIDERED 05/26/2006				
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

				ATTY DOCKET NO. 022438.43867		APPLICATION NO. 09/965.738			
				APPLICANT(S) O'Brien, et al.					
				FILING DATE September 27, 2001		GROUP ART UNIT			
U.S. PATENT DOCUMENTS									
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
U.S. PATENT APPLICATION PUBLICATIONS									
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
FOREIGN PATENT DOCUMENTS									
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
							YES	NO	
PR	AA	WO 00/36107	06/22/00	World	C12N 15/12	C07K 14/47	✓		
PR	BB	0 288 082	10/26/88	Europe	C07K 15/14	C12P 21/00	✓		
PR	CC	WO 02/092836	11/21/02	World	C12Q		✓		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)									
PR		DD	"More than 15 years of CA125: What is known about the antigen, its structure and its function" T.J. O'Brien, et al. The International Journal of Biological Markers, Vol. 13, no. 4, pp. 188-195						
PR		EE	"Isolation and Characterization of Ovarian Cancer Antigen CA125 Using a New Monoclonal Antibody (VK-8): Identification as a Mucin-type Molecule" Kenneth O. Lloyd, et al. Int. J. Cancer: 71, 842-850 (1997)						
EXAMINER /Peter Reddig/				DATE CONSIDERED 05/26/2006					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

 INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		Docket Number (Optional) 022438.43867	Application Number 09/965,738
		Applicant(s) O'Brien, et al.	
		Filing Date September 27, 2001	Group Art Unit
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
PR	FF	"Immunohistochemical Characterization of 22 Monoclonal Antibodies against the CA125 Antigen 2nd Report from the ISOBM TD-1 Workshop" M. Nap, et al. Tumor Biol. 1996: 17: 325-331	
PR	GG	"Human Mucin Gene MUC5B, the 10.7-kb Large Central Exon Encodes Various Alternate Subdomains Resulting in a Super-repeat" Jean-Luc Desseyn, et al. The Journal of Biological Chemistry, Vol. 272, No. 6, Issue of February 7, pp. 3168-3178 (1997)	
PR	HH	"Isolation of the Murine Nbr1 Gene Adjacent to the Murine Brca1 Gene" Julie Chambers, et al. Genomics 38, 305-313 (1996)	
PR	II	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=2566012 "Nucleotide" Lee Helman, M.D., et al. NCBI Sequence Viewer	
PR	JJ	"Molecular Cloning of the CA125 Ovarian Cancer Antigen" Beatrice W.T. Yin, et al. The Journal of Biological Chemistry, Vol. 276, No. 29, Issue of July 20, pp. 27371-27375 (2001)	
PR	KK	"The CA125 Gene: An Extracellular Superstructure Dominated by Repeat Sequences" Timothy J. O'Brien, et al. Tumor Biol. 2001; 22: 348-366	
PR	LL	"The CA125 Gene: A Newly Discovered Extension of the Glycosylated N-Terminal Domain Doubles the Size of This Extracellular Superstructure" Timothy J. O'Brien, et al. Tumor Biol 2002; 23: 154-169	
EXAMINER /Peter Reddig/		DATE CONSIDERED 05/26/2006	
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

+

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

Complete if Known

Application Number	09/965,738
Filing Date	September 27, 2009
First Named Inventor	O'Brien, Timothy J.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	40715-260477

Express Mail Certificate	EV 032 104 775 US
--------------------------	-------------------

MAR 11 2002

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	/Peter Reddig/	Date Considered	05/26/2006
--------------------	----------------	-----------------	------------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.



Substitute for form 1449APTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/965,738
		Filing Date	September 27, 2001
		First Named Inventor	O'Brien, Timothy J.
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
		Attorney Docket Number	40715-260477
Sheet	2	of	3



OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
PR	1	BAST RC et al., A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer, <i>N Engl J Med.</i> 309:883-887 (1983)	✓
PR	2	BON GC et al., Serum tumor marker immunoassays in gynecologic oncology: Establishment of reference values, <i>Am J Obstet. Gynecol.</i> 174:107-114 (1996)	✓
PR	3	CLEMONS-MILLER, A et al. Intrathecal Cytotoxic T-Cell Immunotherapy for Metastatic Leptomeningeal Melanoma. <i>Clinical Cancer Research</i> 7:917s-924s, March 2001 (Suppl.)	✓
PR	4	DESSEYN JL et al., Human mucin gene MUC5B, the 10.7-kb large central exon encodes various alternate subdomains resulting in a super-repeat. Structural evidence for a 11p15.5 gene family, <i>J Biol. Chem.</i> 272(6):3168-3178 (1997)	✓
PR	5	FENDRICK, JL et al. Characterization of CA 125 Synthesized by the Human Epithelial Amnion WISH Cell Line. <i>Tumor Biol</i> 1993; 14:310-318	✓
PR	6	FENDRICK, JL et al. CA125 Phosphorylation Is Associated with Its Secretion from the WISH Human Amnion Cell Line. <i>Tumor Biol</i> 1997; 18:278-289	✓
PR	7	FOON, KA et al., Are solid tumor anti-idotype vaccines ready for prime time?, <i>Clinical Cancer Research</i> 7:1112-1115 (2001)	✓
PR	8	GENDLER SJ et al., Epithelial mucin genes, <i>Annu. Rev. Physiol.</i> 57:607-634 (1995)	✓
PR	9	GUM Jr., JR, Mucin genes and the proteins they encode: Structure, diversity and regulation, <i>Am J Respir. Cell Mol. Biol.</i> 7:557-564 (1992)	✓
PR	10	GUM JR, Human Mucin Glycoproteins: Varied Structures Predict Diverse Properties and Specific Functions. <i>Biochemical Society Transactions.</i> 23(4):795-799, 1995.	✓
PR	11	HARDARDOTTIR H et al., Distribution of CA125 in embryonic tissue and adult derivatives of the fetal periderm, <i>Am J Obstet. Gynecol.</i> 163;6(1):1925-1931 (1990)	✓
PR	12	KONISHI I et al., Epidermal growth factor enhances secretion of the ovarian tumor-associated cancer antigen CA125 from the human amnion WISH cell line, <i>J Soc. Gynecol. Invest.</i> 1:89-96 (1994)	✓
PR	13	LLOYD KO et al., Synthesis and secretion of the ovarian cancer antigen CA125 by the human cancer cell line NIH: OVCAR-3, <i>Tumor Biology</i> 22, 77-82 (2001)	
PR	14	LLOYD KO et al., Isolation and characterization of ovarian cancer antigen CA125 using a new monoclonal antibody (VK-8): Identification as a ucin-type molecule, <i>Int. J. Cancer,</i> 71:842-850 (1997)	✓
PR	15	MARSHALL E, DNA Sequencing: Genome teams adjust to shotgun marriage, <i>Science</i> 292:1982-1983 (2001)	✓
PR	16	NAP M et al., Immunohistochemical characterization of 22 monoclonal antibodies against the CA125 antigen: 2 nd report from the ISOBM TD-1 workshop, <i>Tumor Biology</i> 17:325-331 (1996)	✓
PR	17	NUSTAD K et al., CA125 – epitopes and molecular size, <i>Int. J of Biolog. Markers,</i> 13(4)196-199 (1998)	✓

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449APTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 3

Complete if Known

Application Number	09/965,738
Filing Date	September 27, 2001
First Named Inventor	O'Brien, Timothy J.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	40715-260477


PR	18	NUSTAD K et al., Specificity and affinity of 26 monoclonal antibodies against the CA125 antigen: First report from the ISOBM TD-1 workshop <i>Tumor Biology</i> 17:196-219 (1996)	✓
PR	19	O'BRIEN, TJ et al. CA 125 Antigen in Human Amniotic Fluid and Fetal Membranes. <i>Am J Obstet Gynecol</i> 155:50-55 July, 1986	✓
PR	20	O'BRIEN, TJ et al. New Monoclonal Antibodies Identify the Glycoprotein Carrying the CA 125 Epitope. <i>Am J Obstet Gynecol</i> 1991; 165:1857-64	✓
PR	21	O'BRIEN, TJ et al. More Than 15 Years of CA 125: What Is Known about the Antigen, Its Structure and Its Function. <i>The International Journal of Biological Markers</i> 13:188-195 (1998)	✓
PR	22	QUIRK, JR et al. CA 125 in Tissues and Amniotic Fluid During Pregnancy. <i>Am J Obstet Gynecol</i> 159:655-649 (1988)	✓
PR	23	SANTIN, AD et al. Induction of Ovarian Tumor-Specific CD8+ Cytotoxic T Lymphocytes by Acid-Eluted Peptide-Pulsed Autologous Dendritic Cells. <i>Obstetrics & Gynecology</i> 2000; 96:422-30	✓
PR	24	SANTIN, AD et al. In vitro Induction of Tumor-Specific Human Lymphocyte Antigen Class I-Restricted CD8+ Cytotoxic T Lymphocytes by Ovarian Tumor Antigen-Pulsed Autologous Dendritic Cells from Patients with Advanced Ovarian Cancer. <i>Am J Obstet Gynecol</i> 2000; 183:601-9	✓
PR	25	SHIGESMASA, K, et al. p21: a Monitor of p53 Dysfunction in Ovarian Neoplasia. <i>International Journal of Gynecologic Cancer</i> 7:296-303, 1997.	✓
PR	26	SHIGESMASA, K, et al. p16 Overexpression: A Potential Early Indicator of Transormation in Ovarian Carcinoma. <i>J Soc Gynecol Invest</i> 4:95-102, 1997.	✓
PR	27	VERMA M et al., Mucin genes: Structure, expression and regulation, <i>Glycoconjugate J.</i> 11:172-179 (1994)	✓
PR	27	WAGNER, U. et al. Immunological Responses to the Tumor-Associated Antigen CA125 in Patients with Advanced Ovarian Cancer Induced by the Murine Monoclonal Anti-Idiotypic Vaccine ACA125. <i>HYBRIDOMA</i> 16:33-40 (1997)	✓
PR	29	WAGNER U et al., Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotypic antibody ACA125: Immune responses and survival in palliative treatment, <i>Clin. Cancer Res.</i> 7:1112-1115 (2001)	✓
PR	30	WILLIAMS, SJ et al. MUC13, a Novel Human Cell Surface Mucin Expressed by Epithelial and Hemopoietic Cells. <i>The Journal of Biological Chemistry</i> 276(21):18327-18336, 2001.	✓
PR	31	YIN TWT et al., Molecular cloning of the CA125 ovarian cancer antigen. Identification as a new mucin (MUC16), <i>J Biol. Chem.</i> 276:27371-27375 (2001)	✓
PR	32	ZURAWSKI VR et al., Tissue distribution and characteristics of the CA125 antigen, <i>Cancer Rev.</i> 11-12:102-118 (1998)	✓

Examiner Signature	/Peter Reddig/	Date Considered	05/26/2006
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 611366

**INFORMATION DISCLOSURE CITATION***(Use several sheets if necessary)*

Docket Number (Optional)

022438.43867

Application Number

09/965,738

Applicant(s)

O'Brien, et al.

Filing Date

September 27, 2001

Group Art Unit

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
PR	CC	10/715,066	11/17/03	O'Brien, et al.			11/17/03
PR	DD	10/475,117	10/16/03	O'Brien, et al.			10/16/03

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*


EXAMINER

/Peter Reddig/

DATE CONSIDERED

05/26/2006

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

022438.43867

Application Number

09/965,738

Applicant(s)

O'Brien, et al.

Filing Date

September 27, 2001

Group Art Unit

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

PR

AA

O'Brien, et al.
"The CA125 Gene: An Extracellular Superstructure Dominated by Repeat Sequences"
Tumor Biology, Vol. 22, 2001 pp. 348-366

PR

BB

Argueso, et al.
"MUC16 Mucin is Expressed by the Human Ocular Surface Epithelia and Carries the H185 Carbohydrate Epitope"
Invest Ophthalmol Vis Sci 2003 Jun;44(6):2487-95

EXAMINER

/Peter Reddig/

DATE CONSIDERED

05/26/2006

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.